Form 4: Biohaven CEO Vlad Coric Reports Stock Transactions and Option Grants

Biohaven CEO Vlad Coric reported the acquisition of stock options and restricted share units, along with the withholding of shares for tax purposes.

Summary

• Biohaven CEO Vlad Coric reported several transactions involving the company's stock on January 5, 2025.
• These transactions include the acquisition of 14,250 common shares, the withholding of 6,805 shares for tax purposes at a price of $38.64 per share, and the grant of 343,000 stock options.
• Coric also received 57,000 restricted share units, with 14,250 of these units vesting immediately.
• Following these transactions, Coric directly owns 1,796,604 common shares and indirectly owns 1,378,720 shares through various trusts and a 401(k) plan.
• The stock options vest in four equal installments annually starting January 5, 2025, and the restricted share units also vest in four equal installments annually starting January 5, 2025.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, which are generally viewed neutrally to slightly positive as they align management interests with shareholders.

Positives

• The grant of stock options and restricted share units to the CEO aligns his interests with those of the shareholders.
• The vesting schedule of the options and restricted share units encourages long-term commitment from the CEO.

Negatives

• The withholding of shares for tax purposes reduces the number of shares directly held by the CEO.

Risks

• The vesting of stock options and restricted share units is contingent on the CEO's continued service with the company.
• The value of the stock options and restricted share units is subject to the volatility of the company's stock price.

Future Outlook

The stock options and restricted share units vest over the next four years, subject to the CEO's continued service with the company.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the compensation and ownership structure of the company's leadership.

Comparison to Industry Standards

• Stock option and restricted share unit grants are a common form of executive compensation in the biotechnology industry.
• The vesting schedules are typical for such grants, designed to incentivize long-term performance and retention.
• Companies like Amgen, Regeneron, and Vertex also use similar compensation structures for their executives.

Stakeholder Impact

• Shareholders may view the stock option and restricted share unit grants as a positive sign of management's commitment to the company's long-term success.
• Employees may see the CEO's stock ownership as a positive indicator of the company's future prospects.

Key Dates

Keywords

Biohaven, Vlad Coric, stock options, restricted share units, insider trading, executive compensation, share ownership